- Trial Phase
- Phase 3 (completed — two of three Phase 3 trials failed)
- Time to Market
- Unknown — at least 3-5+ years if a new Phase 3 trial is required, with no guarantee of FDA acceptance of the proposed path
- Why 2/10
- No hard dated binary catalyst in the next ~12 months. The PALISADE-4 Phase 3 failure (June 30, 2026) already crashed the stock ~70%. The next event is a non-dated FDA meeting to discuss a new trial pathway. With two failed Phase 3 trials, this drug's probability of approval is severely diminished, and the company's ~$10M market cap reflects that reality.
Fasedienol has now failed two consecutive Phase 3 trials (PALISADE-3 Dec 2025, PALISADE-4 June 2026). The stock traded at ~$2.04 before the PALISADE-4 miss and collapsed to ~$0.25 — a ~$10M market cap. The company plans an FDA meeting for a potential new trial path, but the path to approval looks extremely long and uncertain. Watch for dilution risk as the company may need financing to fund any future trial.
Price Chart
Executive Summary
Fasedienol (PH94B) is Vistagen Therapeutics' lead asset — a first-in-class pherine nasal spray designed to quickly reduce social anxiety by targeting nose-to-brain neural circuits, without systemic absorption. After a positive Phase 3 PALISADE-2 readout in 2023 (stock surged ~1000%), two subsequent Phase 3 trials (PALISADE-3 in Dec 2025 and PALISADE-4 in June 2026) both failed to meet their primary endpoints. The stock lost ~70% on the PALISADE-4 miss. Vistagen plans to discuss a possible registrational path with the FDA using a new multi-dose trial design with a different primary endpoint (LSAS), but the drug's commercial prospects are materially impaired. The company has cash runway into 2027 but faces an uphill regulatory battle with an asset that has now failed twice in pivotal trials.
How It Works
Fasedienol is a "pherine" — a synthetic compound inhaled via a nasal spray. Instead of entering the bloodstream like most drugs, it works locally in the nose, signaling the brain's fear and anxiety circuits (the olfactory-amygdala pathway) to rapidly dampen anxiety. It is designed to work within minutes for on-demand relief, unlike daily oral antidepressants or benzodiazepines.
Trial Status
Three Phase 3 trials completed under the PALISADE program: PALISADE-2 (positive, met primary endpoint with p=0.015 in 2023), PALISADE-3 (failed, Dec 2025), and PALISADE-4 (failed, June 30, 2026 — primary endpoint p=0.427, also missed all secondary endpoints). An open-label extension study is ongoing. Company plans to meet with FDA to discuss a future multi-dose Phase 3 trial using the LSAS scale as primary endpoint, with prior PALISADE-2 data as supportive evidence.
The Two-Sided Case
Upcoming Catalysts
- FDA meeting to discuss a potential new registrational pathway (date not yet set)
- Possible new Phase 3 trial design announcement if FDA alignment is reached
- Open-label extension safety data from PALISADE-3 and PALISADE-4 (ongoing)
- Potential financing/capital raise to fund any future trials
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Vistagen Therapeutics, Inc. 8-K VTGN ·Originating report